Triple-negative breast cancer (TNBC), defined as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) negative, accounts for approximately 10–20% of all breast cancers (Costa et al., 2017). Here, ERBB2 is linked to triple-negative breast carcinoma.